Olmesartan Medoxomil Crescent Pharma (Olmesartan Medoxomil)

Olmesartan medoxil is a pro‑drug that is converted in the body to olmesartan, which selectively blocks the angiotensin II type‑1 (AT1) receptor. This inhibition prevents vasoconstriction and aldosterone release, leading to relaxed blood vessels, reduced fluid retention, and lower blood pressure.

The dose of Olmesartan Medoxil is individualized by the prescribing clinician based on the patient’s blood pressure, renal function, and response to therapy. The prescriber determines the appropriate strength and titration schedule.

Olmesartan Medoxil is contraindicated in pregnancy, especially in the second and third trimesters, because it can cause fetal toxicity. Limited data are available for breastfeeding; therefore, it is generally avoided unless the benefit outweighs potential risk.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Olmesartan belongs to the ARB class, which provides blood‑pressure reduction similar to ACE inhibitors but with a lower incidence of cough and angio‑edema. Compared with calcium‑channel blockers, ARBs act on the renin‑angiotensin system rather than directly relaxing vascular smooth muscle.

Store tablets at temperatures below 25 °C in their original container, protected from moisture and light. Do not expose the product to excessive heat or humidity to maintain potency.

Olmesartan Medoxil tablets are taken orally, usually once daily, with or without food. Patients should follow the prescribing clinician’s instructions regarding timing and whether the medication should be taken with meals.

Serious adverse events include angio‑edema, severe hypotension, acute kidney injury, and hyperkalemia. Patients should seek immediate medical attention if they experience swelling of the face, lips, tongue, or difficulty breathing.

Olmesartan Medoxil should not be used by individuals with known hypersensitivity to olmesartan or any tablet excipients, pregnant women in the second or third trimester, and patients with severe renal artery stenosis or those taking aliskiren concomitantly in diabetes.